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TO THE EDITOR
Nonne–Milroy disease (OMIM x153100)
is an autosomal dominant form of
primary lymphedema caused by muta-
tions in the FMS-like tyrosine kinase 4
(FLT4) gene, encoding the vascular
endothelial growth factor receptor 3
(VEGFR3) involved in development of
the lymphatic system (Iljin et al., 2001;
Ferrell, 2002; Saaristo et al., 2002).
Mutations in FLT4 exhibit strongly
varying penetrance, with women more
often affected (Ferrell, 2002; Evans
et al., 2003). In 96% of cases, the
lymphedema is congenital (Ferrell,
2002). Almost all FLT4 mutations in
Nonne–Milroy disease are heterozygous
missense mutations affecting the intra-
cellular tyrosine kinase domains. Mu-
tant receptors are more stable than their
wild-type (WT) counterpart, exhibiting
an approximately 40% longer half-life
(Karkkainen et al., 2001; Ferrell, 2002).
This results in accumulation of the
mutant receptor on the cell surface
and ligand capture, explaining the
dominant character of FLT4 mutations
(Karkkainen et al., 2000). It might
Abbreviations: ERK, extracellular signal-regulated kinase; FLT4, FMS-like tyrosine kinase 4; HUVEC,
human umbilical vein endothelial cells; VEGF-C, vascular endothelial growth factor C; VEGFR, vascular
endothelial growth factor receptor; WT, wild type
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therefore be expected that compound
heterozygous mutations of FLT4 cause a
more severe phenotype. However, we
report a patient who is compound
heterozygous for FLT4 mutations
but less severely affected than his
heterozygous half sister who has incom-
petence of the greater saphenous vein in
addition to congenital lymphedema.
I-1 I-2 I-3 I-4
II-1 II-2
III-1 III-2
II-3
G933R
G933R
G933R
G933R
D1049N
D1049N
D1049N
G933R D1049N
WT
− + − + − +
G933R D1049NWT
− + − + −
−VEGF-C +VEGF-C
+
170
130
100
72
170
130
100
72
VEGF-C
IP: 9D9f9
IP: 9D9f9
IB: 9D9f9
IB: anti-p-Tyr
VEGF-C
IB: 9D9f9
IB: anti-p-ERK 1/2
IB: anti-ERK 1/2
40
40
170
130
100
72
WT-GFP
Mut-Strep
170
130
170
130
IP: anti-Strep
IP: anti-Strep
IB: anti-p-Tyr
IB: 9D9f9
Un
tra
n
sf
e
ct
ed
W
T:
m
u
t 1
:0
W
T:
m
u
t 3
:1
W
T:
m
u
t 1
:1
W
T:
m
u
t 1
:3
W
T:
m
u
t 0
:1
W
T:
m
u
t 3
:1
W
T:
m
u
t 1
:1
W
T:
m
u
t 0
:1
WT
G933R
D1049N
Figure 1. Phenotype of the patients and functional analysis of the mutants (a) Pedigree and mutations. Filled symbols indicate affected individuals.
(b) Eleven-year-old female index patient (III-1) with prominent varicose veins and swelling of lower limbs and feet. (c) Two-year-old male index patient (III-2)
with lymphedema of left lower limb and foot. (d) VEGF-C stimulation causes phosphorylation of WT- and D1049N-VEGFR3, but not of G933R-VEGFR3.
Upper panel: blot with antiphosphotyrosine antibody. Lower panel: the same volumes were loaded on another gel and blotted with 9D9f9 antibody.
(e) Cross-titrating amounts of differentially tagged VEGFR3 WT and mutants were transiently transfected in 293T cells. Increasing amounts of cotransfected
WT-VEGFR3 does not promote significant tyrosine phosphorylation of G933R. On the other hand, D1049N is readily phosphorylated. (f) Analysis of
downstream signaling of VEGFR3 upon VEGF-C induction. Protein extracts from retrovirally infected HUVEC were prepared and subjected to reducing
SDS-PAGE. Equal amounts of protein were loaded on two gels and western blotting was performed with anti-ERK1/2 and anti-phospho-ERK1/2 antibodies.
Total levels of VEGFR3 were verified with the 9D9f9 antibody. (g) Aliquots from the same cell cultures used for the experiments presented in (d) were processed
for immunofluorescence analysis. WT- and D1049N-VEGFR3-GFP fusion proteins were internalized upon VEGF-C stimulation, whereas G933R-VEGFR3
remained expressed on the cell membrane. The scale bar represents 20mm.
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At first examination, the boy was 2
years old, his sister 11 (pedigree in
Figure 1a). The girl revealed a bilateral
pitting edema of the legs and feet.
Paucity of subcutaneous fatty tissue
and prominent varicose veins were
noticed on the medial sides of both
lower limbs (Figure 1b). Venous ultra-
sound imaging revealed bilateral insuf-
ficiency of the sapheno-femoral
junction and the greater saphenous
vein. The boy showed a unilateral
compressible edema of the left lower
limb and foot (Figure 1c). Abnormalities
like lymphedema or varicose veins
were neither reported nor clinically
visible in the parents. Based on the
medical history of congenital lymphe-
dema and our own examination we
made a diagnosis of Nonne–Milroy
lymphedema and screened the FLT4
gene for pathogenic mutations.
In both siblings we identified a
maternally inherited heterozygous
transversion c.2797G4C (p.G933R) in
the FLT4 gene. This mutation has
been reported previously and has a
variable penetrance (Evans et al.,
2003). Additionally, the boy revealed
a paternally inherited second hetero-
zygous transition c.3145G4A
(p.D1049N). Restriction analysis with
BmgB1 confirmed absence of this se-
quence deviation in 383 unrelated and
unaffected Dutch and 71 German con-
trol individuals of Caucasian back-
ground. G933R is a de novo mutation
in individual II-2 because the maternal
grandparents (I-1 and I-2) did not carry
the mutation and haplotyping con-
firmed paternity in the maternal line-
age. The paternal grandmother
(individual I-4 in Figure 1a) did not carry
the D1049N mutation. As the paternal
grandfather (individual I-3 in Figure 1a)
was deceased, we cannot exclude that he
carried mutation D1049N.
Because of the less severe phenotype
of the boy, we hypothesized that one of
his mutations might be an activating
one, compensating for the effects of the
other. The mutants G933R and
D1049N were expressed in human
umbilical vein endothelial cells (HU-
VEC), stimulated with vascular en-
dothelial growth factor C (VEGF-C),
and analyzed for localization and
phosphorylation of VEGFR3 and its
downstream target extracellular signal-
regulated kinase (ERK)1/2 (details on
Materials and Methods can be found in
Supplementary Material). To test if
G933R-VEGFR3 and D1049N-VEGFR3
are phosphorylated upon VEGF-C sti-
mulation, HUVEC were infected with
retroviruses carrying WT or mutant
VEGFR3-GFP. After immunoprecipita-
tion of VEGFR3 with the 9D9f9 anti-
body (Figure 1d, bottom), the
phosphorylation status of VEGFR3 was
assessed by immunoblotting using an
antiphosphotyrosine antibody (Figure
1d, top). After 10 minutes of stimulation
with 100 ng ml1 VEGF-C, both WT
receptor and D1049N-VEGFR3 are
readily phosphorylated, G933R-
VEGFR3 only very weakly. These re-
sults were confirmed by cotransfection
of varying concentrations of mutant and
WT VEGFR3 in 293T cells (Figure 1e).
After stimulation with VEGF-C for
10 minutes, the WT receptor was phos-
phorylated (data not shown), whereas
G933R-VEGFR3 phosphorylation was
markedly reduced, even at a ratio of
WT:G933R-VEGFR3 of 1:1. Again,
D1049N-VEGFR3 behaved like the
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Figure 2. Heterodimerization of G933R-VEGFR3 with WT- and D1049N-VEGFR3. Cross-titrating amounts of differentially tagged VEGFR3 WT and mutants
were transiently transfected in 293T cells and VEGFR3 was analyzed for tyrosine phosphorylation (a, b, upper panels). Equal amounts of immunoprecipitates
were loaded on a separate gel and blotted with 9D9f9 to show total G933R-VEGFR3 levels (a, b, lower panels). G933R-VEGFR3 was pulled down either with
StrepTactin-Sepharose (a) or with anti-GFP-antibody, followed by Protein G-sepharose capture (b). WT- and D1049N-VEGFR3 carried the opposite label.
G933R-VEGFR3 did not show a higher level of phosphorylation when expressed 1:1 with D1049N as when coexpressed with WT-VEGFR3, regardless of the
label used for pull-down. In order to see any compensatory effect of D1049N, the phosphotyrosine blots were exposed approximately 20 times longer than
that in Figure 1e.
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WT. As VEGF-C/VEGFR3 induces phos-
phorylation of ERK1/2 (Makinen et al.,
2001), we performed western blotting
for phospho-ERK1/2 in HUVEC infected
with WT and mutant VEGFR3. Stimula-
tion with VEGF-C for 10 minutes
induced ERK1/2 activation in WT- and
D1049N-VEGFR3-infected cells, but not
in G933R-VEGFR3-infected HUVEC (Fig-
ure 1f). In addition, whereas WT-VEGFR3
(Figure 1g, top) and D1049N-VEGFR3
(Figure 1g, bottom) were internalized in
small vesicles after 1 hour of stimulation
with 100 ng ml1 VEGF-C, HUVEC in-
fected with G933R-VEGFR3 lacked this
response to VEGF-C (Figure 1g, middle).
In conclusion, D1049N-VEGFR3 did not
show an increased phosphorylation
response upon VEGF-C that would ex-
plain the less severe phenotype of the
compound heterozygous patient. Finally,
we searched for a difference in binding
affinity of G933R-VEGFR3 for D1049N-
VEGFR3 and WT. Enhanced binding
affinity of G933R-VEGFR3 for D1049N-
VEGFR3 compared to that of G933R-
VEGFR3 for WT-VEGFR3 would impli-
cate a preferential heterodimerization in
the compound heterozygous patient (in
contrast to the G933R heterozygous
patient). To address this question cross-
titrating levels of WT or D1049N-
VEGFR3, both GFP-tagged, were cotrans-
fected together with StrepII-tagged
G933R-VEGFR3 in 293T cells (Figure
2a). This experiment was also performed
with the according vice versa tagged
constructs (Figure 2b). After 10 minutes of
stimulation with 100 ng ml1 VEGF-C,
cells were lysed and G933R-VEGFR3
was precipitated using StrepTactin Se-
pharose (Figure 2a) or an anti-GFP-anti-
body (Figure 2b). Subsequently, the
membranes were blotted with the anti-
phosphotyrosine antibody revealing the
level of phosphorylated G933R-VEGFR3
(top) and the 9D9f9 antibody indicating
the level of G933R-VEGFR3 pulled down
(bottom). However, regardless of which
label was used for pulling down G933R,
no difference between the effects of WT
and D1049N on G933R phosphorylation
was observed. Furthermore, we studied
VEGF-C-induced heterodimerization of
WT and mutant VEGFR3 with VEGFR2
(Dixelius et al., 2003). This study showed
that both G933R-VEGFR3 and D1049N-
VEGFR3 are able to interact with
VEGFR2 (data not shown).
In conclusion, we report a patient
with Nonne–Milroy disease associated
with compound heterozygosity for the
G933R and D1049N mutations affect-
ing the tyrosine kinase domains of
VEGFR3. Although a previous report
suggested that D1049N is pathogenic
(Ferrell, 2002), our functional studies
suggest that D1049N might rather con-
stitute a rare polymorphism. Therefore,
the phenotypic difference between both
index patients could result from a
variable penetrance of the G933R
mutation. Overall, it remains intriguing
why a mutation in such an important
gene causes phenotypic abnormalities
limited to the lower limbs, and why the
lymphedema can be unilateral. The
association of lymphedema with early-
onset incompetence of the superficial
venous system, as observed in indivi-
dual III-1, supports previous suggestions
that VEGFR3 might be implicated in
venous patterning, giving new insights
for research on the pathogenesis of
venous incompetence.
The experiments were performed
in accordance to the institutional
regulations. Consent from the parents
and assent from the patients was
obtained in adherence to the Helsinki
guidelines.
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